Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2020 1
2021 2
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Pentraxin 3 in primary percutaneous coronary intervention for ST elevation myocardial infarction is associated with early irreversible myocardial damage : Kinetic profile, relationship to interleukin 6 and infarct size.
Butt N, Bache-Mathiesen LK, Ushakova A, Nordrehaug JE, Jensen SE, Munk PS, Danchin N, Dubois-Rande JL, Hansen HS, Paganelli F, Corvoisier PL, Firat H, Erlinge D, Atar D, Larsen AI. Butt N, et al. Among authors: bache mathiesen lk. Eur Heart J Acute Cardiovasc Care. 2020 Jun;9(4):302-312. doi: 10.1177/2048872620923641. Epub 2020 May 14. Eur Heart J Acute Cardiovasc Care. 2020. PMID: 32403934 Free PMC article. Clinical Trial.
Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins.
Butt N, Bache-Mathiesen LK, Nordrehaug JE, Tuseth V, Munk PS, Bonarjee V, Hall TS, Jensen SE, Halvorsen S, Firat H, Atar D, Larsen AI. Butt N, et al. Among authors: bache mathiesen lk. Cardiology. 2017;138(2):122-132. doi: 10.1159/000475460. Epub 2017 Jun 27. Cardiology. 2017. PMID: 28651249 Free article. Clinical Trial.